COR2ED develops high-quality Independent Medical Education programmes to help healthcare professionals improve the health of patients globally.

Advanced HCC: treatment strategies for patients ineligible for IO or those with progression on IO
3:22
Advanced HCC: treatment strategies for patients ineligible for IO or those with progression on IO
Tackling mPDAC: chemotherapy strategies that matter
21:52
Tackling mPDAC: chemotherapy strategies that matter
Highlights - Tackling mPDAC: chemotherapy strategies that matter
4:32
Highlights - Tackling mPDAC: chemotherapy strategies that matter
ER+/HER2- metastatic breast cancer: Highlights from ESMO Breast Cancer 2025 Satellite Symposium
5:32
ER+/HER2- metastatic breast cancer: Highlights from ESMO Breast Cancer 2025 Satellite Symposium
Tromboprofilaxia în perioperator – trecere în revistă
21:20
Tromboprofilaxia în perioperator – trecere în revistă
Tromboembolismul venos (TEV): cât timp ar trebui să fie administrat tratamentul antitrombotic?
27:52
Tromboembolismul venos (TEV): cât timp ar trebui să fie administrat tratamentul antitrombotic?
Cancerul și tromboza
28:50
Cancerul și tromboza
The HER2 diagnostic and treatment landscape in NSCLC
18:35
The HER2 diagnostic and treatment landscape in NSCLC
LEAP-012 study: Expert insights on multimodal treatment for intermediate HCC
5:13
LEAP-012 study: Expert insights on multimodal treatment for intermediate HCC
Optimising novel therapy sequencing from early relapse in multiple myeloma: Prof Hermann Einsele
2:17
Optimising novel therapy sequencing from early relapse in multiple myeloma: Prof Hermann Einsele
Optimising novel therapy sequencing from early relapse in multiple myeloma: Prof Evangelos Terpos
1:49
Optimising novel therapy sequencing from early relapse in multiple myeloma: Prof Evangelos Terpos
Understanding Rare NSCLC Mutations: Insights, access and support
20:35
Understanding Rare NSCLC Mutations: Insights, access and support
Understanding Rare NSCLC Mutations: Insights, access and support
5:04
Understanding Rare NSCLC Mutations: Insights, access and support
Living with BRAF-mutated NSCLC
5:16
Living with BRAF-mutated NSCLC
ADCs in HR+/HER2- mBC
9:16
ADCs in HR+/HER2- mBC
Living with HER2-mutated NSCLC
4:27
Living with HER2-mutated NSCLC
The expanding role of immunotherapy in HCC
4:30
The expanding role of immunotherapy in HCC
Highlights: The HER2 diagnostic and treatment landscape in NSCLC
4:11
Highlights: The HER2 diagnostic and treatment landscape in NSCLC
Elacestrant in ER+/HER2- mBC with ESR1-mut tumors: Overview of the EMERALD subgroup analyses
8:53
Elacestrant in ER+/HER2- mBC with ESR1-mut tumors: Overview of the EMERALD subgroup analyses
The HER2 Diagnostic and Treatment Landscape in NSCLC
5:59
The HER2 Diagnostic and Treatment Landscape in NSCLC
The HER2 Diagnostic and Treatment Landscape in NSCLC
21:27
The HER2 Diagnostic and Treatment Landscape in NSCLC
Survey on the evolving role of the oncology nurse in the USA
7:25
Survey on the evolving role of the oncology nurse in the USA
The patient perspective: Living with NSCLC driven by a rare alteration.
8:08
The patient perspective: Living with NSCLC driven by a rare alteration.
PARP inhibitors in combination with NHAs (SHORT)
6:00
PARP inhibitors in combination with NHAs (SHORT)
PARP inhibitor monotherapy
5:06
PARP inhibitor monotherapy
Precision oncology in gastric cancer: tips for optimal biomarker testing
4:04
Precision oncology in gastric cancer: tips for optimal biomarker testing
Precision oncology in prostate cancer: tips for optimal genomic testing
5:51
Precision oncology in prostate cancer: tips for optimal genomic testing
2nd line chemotherapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)
6:17
2nd line chemotherapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)
1st line chemotherapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)
7:22
1st line chemotherapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)
The latest NSCLC data presented at ELCC 2025
5:35
The latest NSCLC data presented at ELCC 2025